Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
ACTIVE_NOT_RECRUITING
Status
Conditions
- Malignant Solid Neoplasm
- Recurrent Adrenal Gland Pheochromocytoma
- Recurrent Ectomesenchymoma
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Kidney Wilms Tumor
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Melanoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdoid Tumor of the Kidney
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent Thyroid Gland Carcinoma
- Recurrent WHO Grade 2 Glioma
- Refractory Adrenal Gland Pheochromocytoma
- Refractory Ependymoma
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Melanoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Rhabdoid Tumor of the Kidney
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Refractory Thyroid Gland Carcinoma
- Refractory WHO Grade 2 Glioma
Interventions
Sponsor
National Cancer Institute (NCI)